25,729 articles
Taishan Panshi San
泰山磐石散 (Taishan Panshi San), also 泰山磐石饮, a 12-ingredient Ming-dynasty Chinese medicine formula from Jingyue Quanshu that tonifies qi and blood to secure the fetus against threatened and habitual miscarriage.
Taiyin Yang
Taiyin Yang is a pharmaceutical development scientist who retired in 2022 as an executive at Gilead Sciences and was elected to the National Academy of Engineering.
Takabb Anti-Cough Pill
Takabb Anti-Cough Pill (ยาอมแก้ไอ ตราตะขาบ 5 ตัว, "five centipedes") is a Thai herbal cough lozenge by Hatakabb (Sim Tien Hor), FDA-registered G 859/45, sold widely including duty-free shops.
Takayasu's arteritis
Takayasu's arteritis (pulseless disease, TAK) is a rare chronic granulomatous large-vessel vasculitis of the aorta and its branches, mainly in young women, causing stenosis, aneurysms, stroke, and hypertension.
Takeda Pharmaceutical Company (武田薬品工業株式会社)
Takeda Pharmaceutical Company Limited (武田薬品工業株式会社), Japanese biopharmaceutical company founded 1781 in Osaka; acquired Shire in 2019; TSE 4502/NYSE TAK; FY2025 revenue USD 28.3 billion, ~50,000 employees, ~80 countries.
Takenouchi-Kosaki syndrome
Takenouchi-Kosaki syndrome (OMIM 616737), a rare CDC42-related congenital disorder: de novo p.Tyr64Cys hot-spot variant causing intellectual disability, macrothrombocytopenia, camptodactyly, sensorineural deafness, hypothyroidism, immunodeficiency, and lymphedema.
Takotsubo cardiomyopathy
Takotsubo cardiomyopathy (broken heart syndrome, stress cardiomyopathy, apical ballooning) is a stress-triggered, transient left ventricular dysfunction mimicking heart attack, affecting mostly postmenopausal women, driven by catecholamine surges, with 4–5% in-hospital mortality and no specific proven treatment.
Talabostat
Talabostat (Val-boroPro, PT-100, BXCL701) is an amino boronic dipeptide inhibiting dipeptidyl peptidases including FAP and DPP4, and the first FAP/DPPIV inhibitor in cancer clinical trials.
Talactoferrin alfa
Talactoferrin alfa (talactoferrin, TLF, LF00) is an oral recombinant human lactoferrin made in Aspergillus niger, developed by Agennix as an immunomodulatory drug; cancer and sepsis phase III trials failed.
Talaporfin
Talaporfin sodium (mono-L-aspartyl chlorin e6, NPe6, Laserphyrin) is a second-generation plant-derived photosensitizer for photodynamic therapy, activated at 664 nm, approved in Japan for early lung cancer, brain tumors, and recurrent esophageal cancer, with shorter skin photosensitivity than porfimer sodium.
TALAPRO-2 trial
TALAPRO-2 (NCT03395197) is Pfizer's phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer, with all-comer and HRR-deficient cohorts; it met its rPFS endpoint and supported FDA (June 2023) and EMA (November 2023) approvals.
Talaromycosis
Talaromycosis (formerly penicilliosis) is an invasive fungal infection from Talaromyces marneffei, endemic to Southeast Asia, southern China, and northeastern India, mainly affecting people with advanced HIV; treated with amphotericin B then itraconazole.
Talazoparib
Talazoparib (BMN 673, Talzenna) is an oral PARP1/2 inhibitor for BRCA-mutated HER2-negative breast cancer and, with enzalutamide, prostate cancer; the strongest PARP-trapping PARP inhibitor, dosed at 1 mg daily.
Talbutal
Talbutal (Lotusate, Profundol), 5-allyl-5-sec-butylbarbituric acid, is an intermediate-acting sedative-hypnotic barbiturate similar to pentobarbital, US Schedule III, with very limited current use and no WHO international scheduling.
Taldefgrobep alfa
Taldefgrobep alfa (BHV-2000, BMS-986089, RG6206) is a fully human anti-myostatin adnectin fusion protein by Biohaven, formerly BMS/Roche; DMD development ended 2019 after SPITFIRE futility, and it is now in Phase 3 SMA (RESILIENT) and Phase 2 obesity trials.
Taletrectinib adipate (AB-106, DS-6051b)
Taletrectinib adipate (AB-106, DS-6051b; Dabole/达伯乐, Ibtrozi) is an oral, CNS-active, selective next-generation ROS1 TKI for ROS1-positive advanced NSCLC, approved in China (2024), the US (2025), and Japan (2025), with activity against the G2032R resistance mutation.
Taliglucerase alfa
Taliglucerase alfa (Elelyso, Uplyso, prGCD) is a carrot-cell expressed recombinant glucocerebrosidase, the first FDA-approved plant-derived biologic (May 1, 2012), enzyme replacement therapy for type 1 Gaucher disease; refused EU authorization.
Talipes calcaneovalgus
Talipes calcaneovalgus, also called congenital talipes calcaneovalgus (ICD-10 Q66.4, ICD-11 LB98.22), is a flexible congenital foot deformity with the ankle dorsiflexed and forefoot deviated outward, affecting about 5 percent of newborns, treated with stretching, splinting, or casting, with an excellent prognosis.
Talipes calcaneovarus
Talipes calcaneovarus (ICD-10 Q66.1, HPO HP:0008124) is a congenital foot deformity combining talipes calcaneus and talipes varus: a dorsiflexed, inverted, adducted foot, a clubfoot form distinct from talipes equinovarus and calcaneovalgus.
Tall stature-intellectual disability-renal anomalies syndrome
Tall stature-intellectual disability-renal anomalies syndrome, also called Thauvin-Robinet-Faivre syndrome (TROFAS), is a rare autosomal recessive overgrowth disorder caused by biallelic loss-of-function variants in the FIBP gene.
Talquetamab
Talquetamab (Talvey, talquetamab-tgvs), Janssen Biotech's bispecific GPRC5D x CD3 T-cell engager antibody for relapsed/refractory multiple myeloma; FDA accelerated approval August 2023, boxed warning CRS and ICANS, Tecvayli-Talvey REMS.
Talquetamab plus teclistamab regimen
The talquetamab plus teclistamab regimen is an investigational combination immunotherapy for relapsed or refractory multiple myeloma, pairing two bispecific antibodies targeting GPRC5D and BCMA, studied in the RedirecTT-1 trial.
Talus bone
Talus bone (astragalus): the ankle tarsal bone linking tibia and fibula to the foot. No muscle attachments, tenuous blood supply; fractures carry 25-29% avascular necrosis and 43-64% osteoarthritis rates.
Tambotatug pelitecan
YL201 (Tam-Peli, tambotatug pelitecan, RG6919) is a B7-H3-targeting antibody-drug conjugate from MediLink Therapeutics' TMALIN platform, DAR 8, licensed to Roche in 2026 for $570 million upfront, in phase 3 for SCLC and NPC.
Tamibarotene
Tamibarotene (Am80, Amnolake, SY-1425) is an oral synthetic retinoid, selective RARα/β agonist, about ten times more potent than ATRA in vitro; approved in Japan (2005) for relapsed/refractory acute promyelocytic leukemia and studied in RARA-overexpressing AML and MDS.
Tamoxifen
Tamoxifen (Nolvadex, Soltamox) is a SERM that blocks estrogen in breast tissue; developed from the failed contraceptive ICI 46,474 and approved in 1973, it treats and prevents ER-positive breast cancer, cutting breast cancer deaths by about a third, with endometrial cancer and blood clot risks.
Tamoxifen regimen
A tamoxifen regimen is a drug treatment schedule built around oral tamoxifen, 20 mg daily, given for about 5 years to treat hormone receptor-positive breast cancer and reduce recurrence.
Tampon
Tampon: absorbent cotton or rayon device inserted vaginally to absorb menstrual flow; FDA-regulated as a single-use medical device; patented with applicator by Earle Haas (Tampax, 1936); main risk is rare toxic shock syndrome from Staphylococcus aureus.
Tamra bhasma
Tamra bhasma (copper ash, copper calx) is an Ayurvedic incinerated copper preparation made by Shodhana, Marana, and Amritikarana; used in small doses for anemia, asthma, and liver disorders, with safety dependent on proper purification.
Tamsulosin
Tamsulosin, marketed as Flomax and generics, is a selective alpha-1 adrenoceptor antagonist used to treat benign prostatic hyperplasia, an enlargement of the prostate obstructing urine flow.